300765 石药创新
已收盘 08-06 15:00:00
资讯
新帖
简况
股市必读:石药创新(300765)8月4日董秘有最新回复
证券之星 · 08-05 01:13
股市必读:石药创新(300765)8月4日董秘有最新回复
石药创新:公司生产经营活动一切正常
证券之星 · 08-04 17:27
石药创新:公司生产经营活动一切正常
石药创新(300765.SZ)子公司SYS6090启动Ib/II期临床试验
智通财经 · 08-03
石药创新(300765.SZ)子公司SYS6090启动Ib/II期临床试验
石药创新:公司将依据合同条款和企业会计准则对阿斯利康首付款进行会计处理
证券之星 · 07-31
石药创新:公司将依据合同条款和企业会计准则对阿斯利康首付款进行会计处理
石药创新:公司2026年半年度业绩预告已于2026年7月27日披露
证券之星 · 07-31
石药创新:公司2026年半年度业绩预告已于2026年7月27日披露
石药创新(300765.SZ)子公司SYS6041启动Ⅱ期临床试验
智通财经网 · 07-31
石药创新(300765.SZ)子公司SYS6041启动Ⅱ期临床试验
7月30日石药创新跌5.26%,工银前沿医疗股票A基金重仓该股
证券之星 · 07-30
7月30日石药创新跌5.26%,工银前沿医疗股票A基金重仓该股
石药创新最新公告:控股子公司CRB-701获美国FDA批准启动注册性临床试验
证券之星 · 07-29
石药创新最新公告:控股子公司CRB-701获美国FDA批准启动注册性临床试验
7月28日石药创新涨6.81%,工银前沿医疗股票A基金重仓该股
证券之星 · 07-28
7月28日石药创新涨6.81%,工银前沿医疗股票A基金重仓该股
石药创新(300765)披露2026年半年度业绩预告,7月27日股价下跌1.3%
证券之星 · 07-27
石药创新(300765)披露2026年半年度业绩预告,7月27日股价下跌1.3%
石药创新:预计2026年1-6月扣非后净利润盈利11.5亿元至13.3亿元
证券之星 · 07-27
石药创新:预计2026年1-6月扣非后净利润盈利11.5亿元至13.3亿元
石药创新(300765.SZ)发预盈,预计上半年归母净利润11.8亿元至13.6亿元,同比扭亏为盈
智通财经 · 07-27
石药创新(300765.SZ)发预盈,预计上半年归母净利润11.8亿元至13.6亿元,同比扭亏为盈
石药创新:预计上半年净利11.80亿元-13.60亿元,同比扭亏为盈
格隆汇 · 07-27
石药创新:预计上半年净利11.80亿元-13.60亿元,同比扭亏为盈
石药创新(300765)披露控股子公司恩维曲妥珠单抗注射液上市申请获得受理的公告,7月17日股价下跌4.3%
证券之星 · 07-17
石药创新(300765)披露控股子公司恩维曲妥珠单抗注射液上市申请获得受理的公告,7月17日股价下跌4.3%
石药创新(300765.SZ)控股子公司SYS6043启动Ⅲ期临床试验
智通财经 · 07-16
石药创新(300765.SZ)控股子公司SYS6043启动Ⅲ期临床试验
7月15日石药创新涨12.33%,工银前沿医疗股票A基金重仓该股
证券之星 · 07-15
7月15日石药创新涨12.33%,工银前沿医疗股票A基金重仓该股
7月9日石药创新涨7.47%,工银前沿医疗股票A基金重仓该股
证券之星 · 07-09
7月9日石药创新涨7.47%,工银前沿医疗股票A基金重仓该股
石药创新(300765)披露2026年第三次临时股东会决议公告,7月8日股价下跌0.91%
证券之星 · 07-08
石药创新(300765)披露2026年第三次临时股东会决议公告,7月8日股价下跌0.91%
7月3日石药创新涨6.44%,工银前沿医疗股票A基金重仓该股
证券之星 · 07-03
7月3日石药创新涨6.44%,工银前沿医疗股票A基金重仓该股
石药创新(300765)披露股票交易异常波动公告,7月2日股价上涨12.16%
证券之星 · 07-02
石药创新(300765)披露股票交易异常波动公告,7月2日股价上涨12.16%
加载更多
公司概况
公司名称:
石药创新制药股份有限公司
所属行业:
食品制造业
上市日期:
2019-03-22
主营业务:
石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一,已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
发行价格:
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":40,"timestamp":1785999834000,"preClose":38,"halted":0,"volume":25192372,"delay":0,"changeRate":0.0526,"floatShares":1405000000,"shares":1405000000,"eps":-0.2194,"marketStatus":"已收盘","change":2,"latestTime":"08-06 15:00:00","open":38.29,"high":40.32,"low":37.01,"amount":984000000,"amplitude":0.0871,"askPrice":40,"askSize":6535,"bidPrice":39.99,"bidSize":372,"shortable":0,"etf":0,"ttmEps":-0.2194,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786066200000},"marketStatusCode":5,"adr":0,"adjPreClose":38,"symbolType":"stock","openAndCloseTimeList":[[1785979800000,1785987000000],[1785992400000,1785999600000]],"highLimit":41.8,"lowLimit":34.2,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":20.71,"roa":"--","roe":"--","epsLYR":-0.1731,"committee":-0.781115,"marketValue":56184000000,"turnoverRate":0.0179,"status":0,"floatMarketCap":56184000000},"requestUrl":"/m/hq/s/300765","defaultTab":"news","newsList":[{"id":"2657568178","title":"股市必读:石药创新(300765)8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657568178?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:13","pubTimestamp":1785863602,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,石药创新报收于37.36元,上涨2.86%,换手率0.96%,成交量13.48万手,成交额5.05亿元。董秘最新回复投资者: 您好,创新药板块整体表现低迷,如果公司在这时候能够有回购计划,将会提振中小股东的持股信心!希望能够向董事会反馈董秘: 您好,感谢您的关注与建议,我们会将您的意见转达,谢谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539047","title":"石药创新:公司生产经营活动一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539047?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:27","pubTimestamp":1785835632,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,请问公司股价持续下跌是否已经触及异动披露标准?对比同行业明显公司股价下行更多。请问公司是否经营正常?是否有利空消息没有对投资者进行公布?石药创新回复:您好!公司生产经营活动一切正常,不存在应披露而未披露事项。公司将持续做好经营管理工作,努力提升内在价值。感谢您的关注与支持!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400028995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656027321","title":"石药创新(300765.SZ)子公司SYS6090启动Ib/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2656027321","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656027321?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:33","pubTimestamp":1785746028,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新 发布公告,公司的控股子公司石药集团巨石生物制药有限公司已于近日启动一项评价SYS6090注射液联合治疗在晚期或转移性结直肠癌参与者中的安全性、耐受性及有效性的Ib/Ⅱ期临床试验。未来,公司将基于该研究的结果,继续推进SYS6090注射液联合治疗在结直肠癌参与者中的Ⅲ期确证性临床研究,进一步验证SYS6090注射液联合治疗方案的临床价值。目前,SYS6090-008研究的参与者招募与筛选工作正在积极推进中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBQ","300765","BMED","MDTX","BK0226","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655351077","title":"石药创新:公司将依据合同条款和企业会计准则对阿斯利康首付款进行会计处理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655351077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655351077?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:24","pubTimestamp":1785489866,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问:公司已公告收到阿斯利康授权协议首付款4.2亿美元,这4.2亿美元上半年不确认收益吗?如果确认收益则公司净利润应该同比大幅增长,但到现在也没看到公司的预增公告,请问这4.2亿美元不能确认收入吗?石药创新回复:您好,感谢您对公司的关注,2026年半年度业绩预告已于2026年7月27日披露,公司将依据合同条款和企业会计准则对阿斯利康首付款进行会计处理,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100028935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655351788","title":"石药创新:公司2026年半年度业绩预告已于2026年7月27日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2655351788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655351788?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:21","pubTimestamp":1785489670,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新(300765)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司是否发布中报业绩预告?石药创新回复:您好,感谢您对公司的关注,公司2026年半年度业绩预告已于2026年7月27日披露,谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100028837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356562","title":"石药创新(300765.SZ)子公司SYS6041启动Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356562","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655356562?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:26","pubTimestamp":1785486385,"startTime":"0","endTime":"0","summary":"石药创新(300765.SZ)发布公告,公司的控股子公司石药集团巨石生物制药有限公司(以下简称“巨石生物”)已于近日启动一项评价SYS6041联合用药治疗复发性卵巢癌的有效性和安全性的开放、多队列、多中心II期临床试验。","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/19.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/19.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300765","PSYK","IBBQ","BMED","MDTX","IBBJ","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655182251","title":"7月30日石药创新跌5.26%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655182251","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655182251?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:56","pubTimestamp":1785401800,"startTime":"0","endTime":"0","summary":"证券之星消息,7月30日石药创新跌5.26%,收盘报36.0元,换手率1.3%,成交量18.28万手,成交额6.69亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655865122","title":"石药创新最新公告:控股子公司CRB-701获美国FDA批准启动注册性临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2655865122","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655865122?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:50","pubTimestamp":1785318646,"startTime":"0","endTime":"0","summary":"石药创新(300765.SZ)公告称,公司控股子公司石药集团巨石生物制药有限公司授权开发的CRB-701(SYS6002)被美国FDA批准启动用于二线口咽鳞状细胞癌(OPSCC)适应症的注册性临床试验(试验代号:TEMPO-1)。该药物是一种靶向Nectin-4的新一代抗体药物偶联物(ADC),此前已获两项快速通道资格认定。Corbus预计于2026年第三季度启动患者入组。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900029738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654077172","title":"7月28日石药创新涨6.81%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654077172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654077172?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:57","pubTimestamp":1785229040,"startTime":"0","endTime":"0","summary":"证券之星消息,7月28日石药创新涨6.81%,收盘报38.9元,换手率2.43%,成交量34.13万手,成交额13.12亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800027075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654456040","title":"石药创新(300765)披露2026年半年度业绩预告,7月27日股价下跌1.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654456040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654456040?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:03","pubTimestamp":1785160995,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘,石药创新报收于36.42元,较前一交易日下跌1.3%,最新总市值为511.55亿元。该股当日开盘36.43元,最高37.99元,最低35.82元,成交额达5.83亿元,换手率为1.13%。公司于2026年7月27日披露《2026年半年度业绩预告》。公告显示,石药创新制药股份有限公司预计2026年上半年归属于上市公司股东的净利润为118,000万元至136,000万元,上年同期为亏损274.61万元,实现扭亏为盈。本次业绩预告未经审计,具体数据以半年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654019323","title":"石药创新:预计2026年1-6月扣非后净利润盈利11.5亿元至13.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654019323","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654019323?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:00","pubTimestamp":1785146444,"startTime":"0","endTime":"0","summary":"证券之星消息,石药创新发布业绩预告,预计2026年1-6月扣非后净利润盈利11.5亿元至13.3亿元。巨石生物已于2026年5月29日全额收到阿斯利康支付的4.2亿美元首付款。报告期内,根据协议履约义务及相关会计准则的规定,巨石生物已对部分首付款予以收入确认。石药创新2026年一季报显示,一季度公司主营收入6.65亿元,同比上升40.82%;归母净利润-9385.47万元,同比下降248.88%;扣非净利润-1.11亿元,同比下降262.55%;负债率57.0%,投资收益-505.0万元,财务费用2078.98万元,毛利率41.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700023776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654901639","title":"石药创新(300765.SZ)发预盈,预计上半年归母净利润11.8亿元至13.6亿元,同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2654901639","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654901639?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:33","pubTimestamp":1785144808,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新(300765.SZ)发布2026年半年度业绩预告,预计上半年归属于上市公司股东的净利润11.8亿元至13.6亿元,同比扭亏为盈。报告期内,公司持续加大研发创新投入,重点布局抗体药物、 ADC及mRNA疫苗等前沿技术平台,稳步推进生物制药业务的管线的研发与产业化进程,产品布局覆盖肿瘤、代谢及自身免疫疾病等多个核心治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药创新(300765.SZ)发预盈,预计上半年归母净利润11.8亿元至13.6亿元,同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654163670","title":"石药创新:预计上半年净利11.80亿元-13.60亿元,同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2654163670","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654163670?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:27","pubTimestamp":1785144458,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652560289","title":"石药创新(300765)披露控股子公司恩维曲妥珠单抗注射液上市申请获得受理的公告,7月17日股价下跌4.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652560289","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652560289?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:19","pubTimestamp":1784297955,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,石药创新报收于38.25元,较前一交易日下跌4.3%,最新总市值为537.26亿元。该股当日开盘40.07元,最高42.0元,最低37.53元,成交额达10.13亿元,换手率为1.85%。公司于近日披露公告,其控股子公司石药集团巨石生物制药有限公司收到国家药品监督管理局的《受理通知书》,其申报的恩维曲妥珠单抗注射液上市申请已获受理。该药品尚需通过国家药监局审评审批方可上市,存在研发风险,短期内对公司业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651141082","title":"石药创新(300765.SZ)控股子公司SYS6043启动Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651141082","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651141082?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:59","pubTimestamp":1784192382,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药创新 发布公告,公司控股子公司石药集团巨石生物制药有限公司已于近日启动一项评价SYS6043对比研究者选择的化疗用于铂耐药晚期卵巢癌、原发性腹膜癌以及输卵管癌参与者的随机、多中心、开放标签的Ⅲ期临床试验。与传统野生型可结芯片段不同,SYS6043可减少淋巴细胞摄取,降低脱靶毒性风险,从而提高治疗安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","300765","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455865","title":"7月15日石药创新涨12.33%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455865?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:36","pubTimestamp":1784104562,"startTime":"0","endTime":"0","summary":"证券之星消息,7月15日石药创新涨12.33%创60日新高,收盘报42.0元,换手率2.42%,成交量33.99万手,成交额13.99亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共43家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","159891","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650420739","title":"7月9日石药创新涨7.47%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650420739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650420739?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:30","pubTimestamp":1783585858,"startTime":"0","endTime":"0","summary":"证券之星消息,7月9日石药创新涨7.47%,收盘报36.38元,换手率1.93%,成交量27.11万手,成交额9.66亿元。重仓石药创新的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共43家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900028694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649991224","title":"石药创新(300765)披露2026年第三次临时股东会决议公告,7月8日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649991224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649991224?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:10","pubTimestamp":1783519827,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,石药创新报收于33.85元,较前一交易日下跌0.91%,最新总市值为475.45亿元。石药创新制药股份有限公司于2026年7月8日召开2026年第三次临时股东会,会议由董事会召集,董事长姚兵主持,现场会议在河北省石家庄市高新区中山东路896号公司会议室举行。通过现场和网络投票的股东共328人,代表股份1,182,283,308股,占公司有表决权股份总数的84.8980%。中小股东对该议案的同意比例为99.8259%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648524816","title":"7月3日石药创新涨6.44%,工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648524816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648524816?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:46","pubTimestamp":1783068386,"startTime":"0","endTime":"0","summary":"证券之星消息,7月3日石药创新涨6.44%创60日新高,收盘报36.71元,换手率2.86%,成交量40.13万手,成交额14.18亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共43家,其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","159891","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685940","title":"石药创新(300765)披露股票交易异常波动公告,7月2日股价上涨12.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648685940?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:22","pubTimestamp":1783002139,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘,石药创新报收于34.49元,较前一交易日上涨12.16%,最新总市值为484.44亿元。该股当日开盘30.9元,最高34.66元,最低30.8元,成交额达13.06亿元,换手率为2.79%。公司于近日披露《关于股票交易异常波动公告》,称其股票交易连续三个交易日收盘价格涨幅偏离值累计超过30%,构成股票交易异常波动。公司及控股股东不存在应披露而未披露的重大事项,股票异常波动期间控股股东未买卖公司股票。公司将于2026年8月21日披露2026年半年度报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786057826166,"stockEarnings":[{"period":"1week","weight":0.1111},{"period":"1month","weight":0.171},{"period":"3month","weight":0.2473},{"period":"6month","weight":0.1765},{"period":"1year","weight":-0.2394},{"period":"ytd","weight":0.109}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":-0.0225},{"period":"3month","weight":-0.0669},{"period":"6month","weight":-0.0406},{"period":"1year","weight":0.0733},{"period":"ytd","weight":-0.0173}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"25432人(较上一季度增加4.81%)","perCapita":"55229股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是恩朗苏拜单抗注射液、注射用奥马珠单抗注射液、咖啡因、阿卡波糖、果维康维生素C咀嚼片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一,已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}